MX2022011238A - Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos. - Google Patents

Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos.

Info

Publication number
MX2022011238A
MX2022011238A MX2022011238A MX2022011238A MX2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A MX 2022011238 A MX2022011238 A MX 2022011238A
Authority
MX
Mexico
Prior art keywords
combinations
probenecid
valproic acid
beta
lactam compounds
Prior art date
Application number
MX2022011238A
Other languages
English (en)
Spanish (es)
Inventor
Michael Dunne
Original Assignee
Iterum Therapeutics International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iterum Therapeutics International Ltd filed Critical Iterum Therapeutics International Ltd
Publication of MX2022011238A publication Critical patent/MX2022011238A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2022011238A 2020-03-11 2021-03-11 Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos. MX2022011238A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062987963P 2020-03-11 2020-03-11
PCT/EP2021/056210 WO2021180857A1 (en) 2020-03-11 2021-03-11 Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof

Publications (1)

Publication Number Publication Date
MX2022011238A true MX2022011238A (es) 2022-10-07

Family

ID=74871410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011238A MX2022011238A (es) 2020-03-11 2021-03-11 Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos.

Country Status (10)

Country Link
US (2) US12128034B2 (cg-RX-API-DMAC7.html)
EP (1) EP4117645A1 (cg-RX-API-DMAC7.html)
JP (1) JP7797401B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220152261A (cg-RX-API-DMAC7.html)
CN (1) CN115190797B (cg-RX-API-DMAC7.html)
AU (1) AU2021235058A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015925A2 (cg-RX-API-DMAC7.html)
CA (1) CA3169900A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011238A (cg-RX-API-DMAC7.html)
WO (1) WO2021180857A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554112B2 (en) 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
CN112739330A (zh) 2019-02-13 2021-04-30 伊泰伦治疗国际有限公司 β-内酰胺化合物和丙磺舒的组合及其用途
CN116650490B (zh) * 2023-06-07 2025-05-20 中国人民解放军海军军医大学 化合物mt-1207在降低尿酸方面的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
CN101897687B (zh) * 2009-05-26 2012-07-04 中国科学院上海生命科学研究院 丙戊酸钠治疗肝脏炎症相关疾病的新用途
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
US11554112B2 (en) * 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
CN112739330A (zh) * 2019-02-13 2021-04-30 伊泰伦治疗国际有限公司 β-内酰胺化合物和丙磺舒的组合及其用途

Also Published As

Publication number Publication date
CN115190797B (zh) 2025-07-11
BR112022015925A2 (pt) 2022-10-04
CN115190797A (zh) 2022-10-14
US20210283112A1 (en) 2021-09-16
AU2021235058A1 (en) 2022-09-01
US12128034B2 (en) 2024-10-29
KR20220152261A (ko) 2022-11-15
WO2021180857A1 (en) 2021-09-16
US20250120953A1 (en) 2025-04-17
JP7797401B2 (ja) 2026-01-13
CA3169900A1 (en) 2021-09-16
JP2023517919A (ja) 2023-04-27
EP4117645A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
MX2024000299A (es) Compuestos antivirales.
JOP20210319B1 (ar) مركبات بيروليدين
PH12022551574A1 (en) Egfr inhibitors
MX2024000230A (es) Inhibidores de cdk2.
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
PH12021552513A1 (en) Pyrrole compounds
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2021009755A (es) Combinaciones de compuestos beta-lactámicos y probenecid, y usos de los mismos.
JOP20240059A1 (ar) المركبات المثبطة إيميدازوبيريدازين il-17
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
PH12022551241A1 (en) Egfr inhibitors
MX2021007258A (es) Composiciones de esparsentan amorfas.
MY207239A (en) Imidazopyridinone compound
PH12021552953A1 (en) Tricyclic compounds
WO2022023447A3 (en) Fused bicyclic raf inhibitors and methods for use thereof
MX2023012004A (es) DERIVADO DEL ÁCIDO BÓRICO QUE ACTÚA COMO INHIBIDOR DE LA ß-LACTAMASA.
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
SG11201810725WA (en) Novel β-lactamase inhibitors
BR112022015925A2 (pt) Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos
MX2021009717A (es) Sulfonamidas biciclicas.
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases